Invasive Fungal Infections Market Expected to Achieve 4.8% CAGR by 2029: Growth Forecast Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

How Large Will the Invasive Fungal Infections Market Size By 2025?
The market size for invasive fungal infections has been on a gradual rise over the past several years. Its estimated size is expected to increase from $7.58 billion in 2024 to $7.96 billion in 2025, showing a compound annual growth rate (CAGR) of 5.0%. Factors such as the global proliferation of infections, hematopoietic stem cell transplants, an aging demographic, hospital-related infections, and environmental factors have all contributed to the growth experienced during the historic period.

How Big Is the Invasive Fungal Infections Market Size Expected to Grow by 2029?
The market size for invasive fungal infections is predicted to experience a stable rise in the coming years, escalating to $9.6 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 4.8%. This anticipated growth over the forecast period can be credited to the global preparedness for health crises, educating the public about health, the emergence of new antifungal agents, the impact of climate change, and the use of interdisciplinary strategies. The forecast period will also witness major trends such as advancements in diagnostic techniques, personalized therapeutic strategies, patient-focused care, combined antifungal therapies, and partnerships for drug research and development.

View the full report here:
https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report

Which Key Market Drivers Powering Invasive Fungal Infections Market Expansion and Growth?
The prevalence of individuals diagnosed with the Human Immunodeficiency Virus (HIV) is predicted to boost the expansion of the invasive fungal infection market. HIV disrupts the immune system, impairing its capacity to fend off diseases. The growing incidence of people with weakened immune systems, due to conditions like HIV or AIDS (acquired immunodeficiency syndrome), amplifies the risk of invasive fungal infections. This scenario provides manufacturers with the chance to produce and distribute highly effective antifungal medications. For instance, in July 2023, The Joint United Nations Programme on HIV/AIDS (UNAIDS), the Switzerland-based United Nations initiative committed to tackling the worldwide HIV/AIDS outbreak, reported that the number of people infected with HIV worldwide jumped to 39 million in 2022, an increase of 3.17% from 37.7 million in 2020. Also, around 1.3 million fresh HIV infections were documented in 2022. This surge in the HIV patient population will, therefore, spur the growth of the invasive fungal infection market. The escalating count of cancer patients is also anticipated to fuel the expansion of the invasive fungal infections market. A cancer patent usually pertains to breakthroughs or technologies linked to cancer detection, therapy, or prevention. Cancer patients, particularly those with impaired immunity, are susceptible to invasive fungal infections (IFIs), grave complications that can potentially put their lives at risk. As reported by the National Cancer Institute in the US, the projected number of cancer survivors by 2040 is 26.0 million. The estimate for those who will survive beyond five years post-cancer diagnosis is set to climb nearly 30%, reaching 16.3 million, over the subsequent decade. These figures underline the consequent growth of the invasive fungal infections market triggered by the increase in cancer patients.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13189&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Invasive Fungal Infections Market?
Leading firms in the invasive fungal infection market are concentrating on pioneering products such as Zisavel capsules to boost treatment effectiveness, enhance patient results, and widen availability for those suffering from severe fungal diseases. Zisavel capsules, a generic antifungal product sourced from isavuconazole, are developed to combat invasive aspergillosis and mucormycosis. The intention behind these 100 mg capsules is to offer an economical choice for patients, therefore broadening access to effective treatment. For example, in October 2023, BDR Pharmaceuticals, which is based in India and specializes in generic and specialty pharmaceuticals, released Zisavel Capsules, a generic antifungal medicine, for treating invasive aspergillosis and mucormycosis. Zisavel is prescribed for the treatment of invasive aspergillosis and mucormycosis, both are serious fungal infections that can potentially be fatal. The launch of Zisavel is intended to make the treatment more reachable to patients by significantly reducing expenses in comparison to current alternatives like voriconazole and posaconazole.

What Are the Emerging Segments in the Invasive Fungal Infections Market?
The invasive fungal infections market covered in this report is segmented -

1) By Disease Type: Candidemia And Invasive Candidiasis, Intra Abdominal Candidiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Other Disease Type
2) By Drug Type: Polyenes, Triazoles, Echinocandins, Flucytosine, Other Drug Type
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:
1) By Candidemia And Invasive Candidiasis: Bloodstream Infections, Disseminated Candidiasis
2) By Intra-Abdominal Candidiasis: Peritoneal Candidiasis, Abscess Formation
3) By Cryptococcal Meningitis: Primary Cryptococcal Meningitis, Secondary Cryptococcal Meningitis
4) By Esophageal Candidiasis: Acute Esophageal Candidiasis, Chronic Esophageal Candidiasis
5) By Histoplasmosis Acute Pulmonary: Disseminated Histoplasmosis, Chronic Pulmonary Histoplasmosis
6) By Other Disease Types: Aspergillosis, Mucormycosis, Other Rare Fungal Infections

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13189&type=smp

Who Are the Global Leaders in the Invasive Fungal Infections Market?
Major companies operating in the invasive fungal infections market report are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK PLC, Gilead Sciences Inc., Siemens Healthineers, Mylan N.V., Astellas Pharma Inc., Quest Diagnostics Incorporated, Sun Pharmaceutical Industries Ltd., BioMérieux SA, BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd., F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB

Which are the Top Profitable Regional Markets for the Invasive Fungal Infections Industry?
North America was the largest region in the invasive fungal infections market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the invasive fungal infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13189

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.